1 Faculty of Dentistry, the University of British Columbia, Vancouver, BC, Canada.
2 BC Oral Cancer Prevention Program, BC Cancer Agency, Vancouver, BC, Canada.
J Dent Res. 2018 Jul;97(7):767-772. doi: 10.1177/0022034517748639. Epub 2018 Jan 12.
Oral lichen planus is categorized as a potentially malignant condition by the World Health Organization; however, some argue that only lichen planus with dysplasia have malignant potential. Many pathologists call lichen planus with dysplasia "dysplasia with lichenoid mucositis (LM)" or "LM with dysplasia." Previous research has shown that certain high-risk patterns of loss of heterozygosity (LOH) in dysplastic lesions are associated with significantly increased cancer risk. However, LM without dysplasia lacks such molecular patterns, supporting the hypothesis that LM, by itself, is not potentially malignant and that only those with dysplasia have malignant potential. To further investigate the premalignant nature of LM with dysplasia, this study compared the rate of malignant progression of dysplasia with LM with that of dysplasia without LM. Patients from a population-based prospective cohort study with >10 y of follow-up were analyzed. Study eligibility included a histological diagnosis of a primary low-grade dysplasia with or without LM. A total of 446 lesions in 446 patients met the selection criteria; 373 (84%) were classified as dysplasia without LM, while 73 (16%) were classified as dysplasia with LM. Demographic and habit information, clinical information, and outcome (progression) were compared between the 2 groups. Forty-nine of 373 cases of dysplasia (13%) progressed compared to 8% (6/73) of dysplasia with LM. However, the difference was not statistically different ( P = 0.24). The 3- and 5-y rate of progression did not differ between the groups (6.7% and 12.5% for dysplasia without LM and 2.9% and 6.6% for those with LM; P = 0.36). Progression was associated with nonsmoking, location at a high-risk site, and diagnosis of moderate dysplasia regardless of whether LM was present or not. Dysplasia with or without LM had similar cancer risk, and dysplasia should not be discounted in the presence of LM.
口腔扁平苔藓被世界卫生组织归类为一种潜在恶性疾病;然而,一些人认为只有具有异型增生的扁平苔藓才有恶性潜能。许多病理学家将具有异型增生的扁平苔藓称为“异型增生伴苔藓样黏膜炎(LM)”或“伴异型增生的 LM”。先前的研究表明,异型增生病变中某些高风险的杂合性丢失(LOH)模式与显著增加的癌症风险相关。然而,无异型增生的 LM 缺乏这种分子模式,这支持了这样一种假说,即 LM 本身并不具有潜在恶性,只有那些具有异型增生的才具有恶性潜能。为了进一步研究具有异型增生的 LM 的癌前性质,本研究比较了具有 LM 的异型增生与无 LM 的异型增生的恶性进展率。对一项具有 >10 年随访的基于人群的前瞻性队列研究的患者进行了分析。研究入选标准包括原发性低级别异型增生的组织学诊断,无论是否存在 LM。共有 446 名患者的 446 处病变符合选择标准;373 处(84%)被归类为无 LM 的异型增生,而 73 处(16%)被归类为伴 LM 的异型增生。比较了两组间的人口统计学和习惯信息、临床信息和结局(进展)。与无 LM 的异型增生相比,伴 LM 的异型增生的 49 例(13%)进展,而 8%(6/73)。然而,差异无统计学意义(P=0.24)。两组间的 3 年和 5 年进展率无差异(无 LM 的异型增生为 6.7%和 12.5%,伴 LM 的异型增生为 2.9%和 6.6%;P=0.36)。进展与不吸烟、高危部位的位置和中度异型增生的诊断相关,无论是否存在 LM 均如此。伴或不伴 LM 的异型增生具有相似的癌症风险,因此不应低估 LM 存在时的异型增生。